Stance Capital’s Novavax NVAX Stock Holding History

Stance Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500	Closed	-$4.07K	–	386
2026 Q1	$4.07K	Buy	+500	New	+$4.53K	﹤0.01%	267
2025 Q4	–	Sell	-500	Closed	-$4.33K	–	244
2025 Q3	$4.33K	Buy	+500	New	+$3.89K	﹤0.01%	266
2025 Q1	–	Sell	-500	Closed	-$4.02K	–	200
2024 Q4	$4.02K	Buy	+500	New	+$4.82K	﹤0.01%	192

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Stance Capital's NVAX Position: Q2 2026 in Review

Stance Capital sold out of Novavax (NVAX) in Q2 2026, closing a stake of 500 shares — an estimated $4.07K sold.

Stance Capital first reported a position in NVAX in Q4 2024 and held it in 3 quarters. The position peaked at $4.33K in Q3 2025. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Stance Capital reported no remaining Novavax position as of Q2 2026 after selling out during the quarter.
Stance Capital sold 500 Novavax shares in Q2 2026, an estimated $4.07K.
Stance Capital first reported a position in Novavax in Q4 2024 and held it in 3 quarters.
Stance Capital's Novavax position peaked at $4.33K in Q3 2025.
267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.